These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21496277)

  • 41. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
    Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.
    Chauhan S; Sen S; Irshad K; Kashyap S; Pushker N; Meel R; Sharma MC
    Hum Cell; 2024 Jan; 37(1):297-309. PubMed ID: 37914903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
    Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
    PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
    Lee YH; Lee MM; De Silva DM; Roy A; Wright CE; Wong TK; Costello R; Olaku O; Grubb RL; Agarwal PK; Apolo AB; Bottaro DP
    PLoS One; 2021; 16(7):e0241766. PubMed ID: 34292953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
    Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
    Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
    Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
    Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.
    Divine LM; Nguyen MR; Meller E; Desai RA; Arif B; Rankin EB; Bligard KH; Meyerson C; Hagemann IS; Massad M; Thaker PH; Hagemann AR; McCourt CK; Powell MA; Mutch DG; Fuh KC
    Oncotarget; 2016 Nov; 7(47):77291-77305. PubMed ID: 27764792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
    Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
    Liu R; Gong M; Li X; Zhou Y; Gao W; Tulpule A; Chaudhary PM; Jung J; Gill PS
    Blood; 2010 Jul; 116(2):297-305. PubMed ID: 20442363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
    Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
    Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
    Yu L; Saile K; Swartz CD; He H; Zheng X; Kissling GE; Di X; Lucas S; Robboy SJ; Dixon D
    Mol Med; 2008; 14(5-6):264-75. PubMed ID: 18231572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
    Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glycoxidised LDL induced the upregulation of Axl receptor tyrosine kinase and its ligand in mouse mesangial cells.
    Kim YS; Jung DH; Sohn E; Kim J; Kim JS
    PLoS One; 2012; 7(11):e50297. PubMed ID: 23226259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer.
    Akgül M; Baykan Ö; Çağman Z; Özyürek M; Tinay İ; Akbal C; Uras F; Türkeri L
    Arch Ital Urol Androl; 2021 Jun; 93(2):148-152. PubMed ID: 34286546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
    Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein kinase C-delta transactivates platelet-derived growth factor receptor-alpha in mechanical strain-induced collagenase 3 (matrix metalloproteinase-13) expression by osteoblast-like cells.
    Yang CM; Hsieh HL; Yao CC; Hsiao LD; Tseng CP; Wu CB
    J Biol Chem; 2009 Sep; 284(38):26040-50. PubMed ID: 19633290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.